| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
PACS Group, Inc.$46.96
-0.12 (-0.25%)
Market Cap
5.30 B
EPS
1.23
P/E Ratio
28.64 $
Value Trade
21.18 M
SEC Financials
Q4 2025Dilution Risk
Revenue
1.36 B
Operating CF
101.06 M
Total Assets
5.58 B
Total Liabilities
4.63 B
Equity
946.77 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
232.05 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Feb 27, 2026
Overview
Volume
726.36 K
52 Week Range
7.50 - 43.08
% held by Insiders
71.74 %
% held by Institutions
30.17 %
Enterprise Value
8.68 B
Total Shares
158.33 M
Short %
10.12 %
Float Shares
46.07 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for PACS Group, Inc.
1Total events
0Upcoming
1Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PACS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PACS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PACS
Jul 28, 2026▼ -0.3%today
PACS Group Schedules Second Quarter 2026 Earnings Release and Conference Call
PACS Group, Inc. has announced its plans to release financial results for the second quarter of 2026 on August 4, 2026. Following this, a conference call will be held on August 5, 2026, at 11:30 a.m. ET to discuss the results. This initiative aims to keep investors informed and engaged.
Read more →-PACS
Jun 29, 2026▲ +6.8%on this news
PACS Group to Acquire Operations of 34 Facilities Across Texas, Montana, New Mexico, North Dakota, South Dakota, and Utah
PACS Group has announced its intention to acquire operations of 34 facilities located in Texas, Montana, New Mexico, North Dakota, South Dakota, and Utah. This strategic move is aimed at expanding their operational footprint across multiple states. The acquisition reflects PACS Group's commitment to enhancing its service offerings in the healthcare sector.
Read more →-PACS
May 11, 2026▼ -5%on this news· ran to +22% by day 1
PACS Group, Inc. Reports First Quarter 2026 Results
PACS Group, Inc. has reported its first quarter results for 2026. However, the article provides minimal information, lacking key financial metrics or insights into the company's performance. The lack of detail raises concerns about transparency and investor confidence.
Read more →-PACS
May 5, 2026PACS Group Intends to Release First Quarter 2026 Earnings on Monday, May 11, 2026, and Host a Call to Discuss Financial Results on Tuesday, May 12, 2026
PACS Group has announced its plans to release its first quarter earnings for 2026 on May 11, 2026. Following the earnings release, the company will host a call on May 12, 2026, to discuss the financial results. This event is part of their regular financial reporting schedule.
Read more →-PACS
Apr 27, 2026PACS Group, Inc. Announces the Appointment of Carey P. Hendrickson as Chief Financial Officer
PACS Group, Inc. has announced the appointment of Carey P. Hendrickson as the new Chief Financial Officer. This leadership change is expected to influence the company's financial strategies moving forward. Further details on Hendrickson's background and plans for the company were not disclosed in the announcement.
Read more →-PACS
Apr 27, 2026PACS Group, Inc. Announces Retirement of Co-Founder and CFO Mark Hancock
PACS Group, Inc. has announced the retirement of co-founder and CFO Mark Hancock. His departure could raise concerns about the company's future leadership and financial direction. The company will need to address the transition to maintain investor confidence and operational stability.
Read more →-PACS
Nov 26, 2024Document PACS NYSE Notice Press Release PACS Group Announces Receipt of Notice of Late Filing from
PACS Group, Inc. recently announced that it received a Filing Delinquency Notification from the NYSE due to delays in filing its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024. The delay is attributed to an ongoing investigation related to third-party allegations, which has hindered timely compliance. PACS Group has a six-month window to submit the report and regain compliance with NYSE regulations. Despite the current compliance issues, the company continues to operate a substantial network of post-acute healthcare facilities across the U.S.
Read more →Competitive Position
How PACS ranks across every disease it competes inCompetitive Position is a premium feature
See how PACS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial